F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.

Autor: Ueda, Shigeto, Saeki, Toshiaki, Shigekawa, Takashi, Omata, Jiro, Moriya, Tomoyuki, Yamamoto, Junji, Osaki, Akihiko, Fujiuchi, Nobuko, Misumi, Misono, Takeuchi, Hideki, Sakurai, Takaki, Tsuda, Hitoshi, Tamura, Katsumi, Ishida, Jiro, Abe, Yoshiyuki, Imabayashi, Etsuko, Kuji, Ichiei, Matsuda, Hiroshi
Předmět:
Zdroj: International Journal of Clinical Oncology; Jun2012, Vol. 17 Issue 3, p276-282, 7p
Abstrakt: Background: To assess the usefulness of positron emission tomography combined with computed tomography using F-fluorodeoxyglucose (FDG PET/CT) for optimizing chemotherapy during neoadjuvant chemotherapy for primary breast cancer. Methods: One hundred and eight patients (110 tumors) with breast cancer (≥2 cm, stages II and III) received neoadjuvant chemotherapy consisting of an anthracycline-based regimen and taxane. The maximal value of the baseline standardized uptake value (SUV) and the change in SUV after four cycles of an anthracycline-based regimen relative to baseline SUV were assessed for predicting pathological complete response (pCR) after sequential taxane. Results: Tumors with pCR had significantly higher baseline SUV (9.3 ± 3.7 SD) compared to those with non-pCR (7.2 ± 3.8 SD) ( p = 0.02), but there was a considerable overlap between two groups. On PET scan after four cycles of chemotherapy, thirty-three patients (33.7%) with a 72.1% or greater reduction in SUV were considered as responders and the performance in predicting pCR had a sensitivity of 88.9% and specificity of 78.7%. Conclusion: The baseline SUV could not be a useful indicator for predicting pCR due to the wide range in sensitivity. On the other hand, a relative change in SUV after completion of an anthracycline-based regimen could be useful for predicting pCR. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: